DOCSLIB.ORG

COUNTY of LUBBOCK Plaintiff

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COUNTY of LUBBOCK Plaintiff Filed 11/12/2019 12:00 AM Barbara Sucsy District Clerk Lubbock County, Texas 2019537688 MS CAUSE NO. __________________ COUNTY OF LUBBOCK § IN THE DISTRICT COURT § Plaintiff, § § vs. § § ________ JUDICIAL DISTRICT TEVA PHARMACEUTICAL INDUSTRIES, § LTD.; § TEVA PHARMACEUTICALS USA, INC.; § CEPHALON, INC.; § ALLERGAN PLC f/k/a ACTAVIS PLC; § ALLERGAN FINANCE, LLC f/k/a § LUBBOCK COUNTY, TEXAS ACTAVIS, INC. f/k/a WATSON § PHARMACEUTICALS, INC.; § ALLERGAN SALES, LLC; § ALLERGAN USA INC.; § WATSON LABORATORIES, INC.; § ACTAVIS LLC; § ACTAVIS PHARMA INC. f/k/a WATSON § PHARMA, INC.; § ACTAVIS LABORATORIES UT, INC. f/k/a § WATSON LABORATORIES, INC.; § JANSSEN PHARMACEUTICALS, INC. f/k/a § ORTHO-MCNEIL-JANSSEN § PHARMACEUTICALS, INC. f/k/a JANSSEN § PHARMACEUTICA, INC.; § JOHNSON & JOHNSON; § NORAMCO, INC.; § ASSERTIO THERAPEUTICS, INC. f/k/a § DEPOMED, INC.; § ENDO HEALTH SOLUTIONS INC.; § ENDO PHARMACEUTICALS INC.; § PAR PHARMACEUTICAL, INC.; § PAR PHARMACEUTICAL COMPANIES, § INC.; § ABBVIE INC.; § KNOLL PHARMACEUTICAL COMPANY; § MALLINCKRODT PLC; § MALLINCKRODT LLC; § SPECGX LLC; § MYLAN INC.; § MYLAN INSTITUTIONAL INC.; § MYLAN PHARMACEUTICALS INC.; § MYLAN SPECIALTY L.P.; § LUBBOCK COUNTY’S ORIGINAL PETITION AND REQUESTS FOR DISCLOSURE Page 1 of 151 MYLAN BERTEK PHARMACEUTICALS § INC.; § MISSION PHARMACAL COMPANY; § MCKESSON CORPORATION; § MCKESSON MEDICAL-SURGICAL INC.; § CARDINAL HEALTH, INC.; § CARDINAL HEALTH 110, LLC; § AMERISOURCEBERGEN CORPORATION; § AMERISOURCEBERGEN DRUG § CORPORATION; § ADVANCED PHARMA, INC. d/b/a § AVELLA OF HOUSTON; § and, § DOES 1 – 99, INCLUSIVE, § § Defendants. § LUBBOCK COUNTY’S ORIGINAL PETITION AND REQUESTS FOR DISCLOSURE Plaintiff, the County of Lubbock, by and through the undersigned attorneys (hereinafter “Lubbock County” or “County”), files this Original Petition and Requests for Disclosure against Defendants Teva Pharmaceutical Industries, LTD., Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Allergan PLC f/k/a Actavis PLC, Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc., Allergan Sales, LLC, Allergan USA Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma Inc. f/k/a Watson Pharma, Inc., Actavis Laboratories UT, Inc. f/k/a Watson Laboratories, Inc., Janssen Pharmaceuticals, Inc. f/k/a Ortho-McNeil-Janssen Pharmaceuticals, Inc. f/k/a Janssen Pharmaceutica, Inc., Johnson & Johnson, Noramco, Inc., Assertio Therapeutics, Inc. f/k/a Depomed, Inc., Endo Health Solutions Inc., Endo Pharmaceuticals, Inc., Par Pharmaceutical, Inc., Par Pharmaceutical Companies, Inc., AbbVie Inc., Knoll Pharmaceutical Company, Mallinckrodt PLC, Mallinckrodt LLC, SpecGx LLC, Mylan Inc., Mylan Institutional Inc., Mylan Pharmaceuticals Inc., Mylan Specialty L.P., Mylan Bertek Pharmaceuticals Inc., Mission Pharmacal Company, McKesson Corporation, McKesson Medical-Surgical Inc., Cardinal Health, Inc., Cardinal Health 110, LLC, AmerisourceBergen Corporation, LUBBOCK COUNTY’S ORIGINAL PETITION AND REQUESTS FOR DISCLOSURE Page 2 of 151 AmerisourceBergen Drug Corporation, Advanced Pharma, Inc. d/b/a Avella of Houston, and, DOES 1 – 99, inclusive (hereinafter collectively “Defendants”), and respectfully shows the Court as follows: LUBBOCK COUNTY’S ORIGINAL PETITION AND REQUESTS FOR DISCLOSURE Page 3 of 151 TABLE OF CONTENTS I. INTRODUCTION .............................................................................................................8 II. RULE 47 STATEMENT OF MONETARY RELIEF SOUGHT ................................15 III. DISCOVERY CONTROL PLAN ..................................................................................15 IV. PARTIES ..........................................................................................................................15 A. Manufacturer Defendants .............................................................................................16 Teva ........................................................................................................................16 Actavis ....................................................................................................................19 J&J .........................................................................................................................22 Depomed ................................................................................................................26 Endo .......................................................................................................................27 AbbVie ....................................................................................................................29 Mallinckrodt ...........................................................................................................31 Mylan .....................................................................................................................33 Mission Pharmacal Company ................................................................................36 B. Distributor Defendants .................................................................................................37 McKesson ...............................................................................................................37 Cardinal .................................................................................................................39 AmerisourceBergen ................................................................................................41 Advanced Pharma ..................................................................................................42 V. JURISDICTION & VENUE ...........................................................................................43 VI. THIS LAWSUIT IS BROUGHT ONLY UNDER TEXAS LAW ...............................44 VII. CONDITIONS PRECEDENT ........................................................................................45 VIII. FACTUAL BACKGROUND ..........................................................................................46 A. The Nationwide Opioid Epidemic ...............................................................................46 LUBBOCK COUNTY’S ORIGINAL PETITION AND REQUESTS FOR DISCLOSURE Page 4 of 151 B. Texas’ Growing Opioid Crisis .....................................................................................47 C. The Opioid Epidemic in Lubbock County ...................................................................50 1. Opioid Prescribing Rates in Lubbock County Have Exceeded State and National Rates for More than a Decade. ................................................................51 2. Lubbock County Residents Report an Increasing Number of Life- Threatening Opioid Exposures. .............................................................................53 3. Lubbock County’s Budget is Strained by Skyrocketing Medical Treatment Costs. ....................................................................................................54 4. Lubbock County’s Criminal Justice System Spends its Limited Resources Fighting a Spiraling Epidemic. .............................................................55 D. Defendants’ Unlawful, False and Deceptive Marketing Practices ..............................56 1. Defendants Aggressively and Unethically Engaged in Direct Marketing of their Branded Opioid Products. .........................................................................57 2. Defendants Used Superficially Independent Third Parties to Engage in False and Deceptive Unbranded Marketing of Prescription Opioids. ...................64 3. Defendants Deployed “Key Opinion Leaders” to Perpetuate Widespread Acceptance of Opioids for the Treatment of Chronic Pain. ..............65 Dr. Russell Portenoy ..................................................................................68 Dr. Lynn Webster .......................................................................................71 Dr. Perry Fine ............................................................................................72 Dr. Scott Fishman ......................................................................................73 4. Defendants Funded and Controlled Industry “Front Groups” to Legitimize their False and Deceptive Messages. ...................................................75 American Pain Foundation ........................................................................76 American Academy of Pain Medicine ........................................................77 5. Defendants Infiltrated Accrediting Institutions to Create a New Standard of Care for the Treatment of Pain and Prescribing of Opioid Drugs ......................................................................................................................80 6. Defendants Targeted Vulnerable Patient Populations. ..........................................83 LUBBOCK COUNTY’S ORIGINAL PETITION AND REQUESTS FOR DISCLOSURE Page 5 of 151 E. Defendants Misrepresented the Safety and Effectiveness of Opioid Drugs ................84 1. Defendants Repeatedly Misrepresented the Risks, Benefits and Superiority of Prescription Opioids for Chronic Pain. ...........................................84 2. Defendants Downplayed and Trivialized the Risks of Long-Term Opioid Use. ............................................................................................................85 3. Defendants Promoted the Term “Pseudoaddiction” and Pushed Prescribers to Treat Addiction with More Opioids. ...............................................93
Load more

Recommended publications
  • Abbvie Allergan Acquisition
    Creating a New Diversified Biopharmaceutical Company The Combination of AbbVie and Allergan Investor Presentation June 25, 2019 NO OFFER OR SOLICITATION This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this presentation is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The acquisition will be made solely by means of the Scheme Document (or, if applicable, the Takeover Offer document), which will contain the full terms and conditions of the acquisition, including details with respect to the AbbVie shareholder vote in respect of the acquisition. Any decision in respect of, or other response to, the acquisition, should be made only on the basis of the information contained in the Scheme Document. IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with the proposed Acquisition, Allergan will file with the Securities Exchange Commission (the “SEC”) a Proxy Statement, which will include the Scheme Document.
    [Show full text]
  • Responding to Mylan's Inadequate Tender Offer
    Responding To Mylan’s Inadequate Tender Offer: Perrigo’s Board Recommends That You Reject the Offer and Do Not Tender September 2015 Important Information Forward Looking Statements Certain statements in this presentation are forward-looking statements. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including future actions that may be taken by Mylan in furtherance of its unsolicited offer. These and other important factors, including those discussed under “Risk Factors” in the Perrigo Company’s Form 10-K for the year ended June 27, 2015, as well as the Company’s subsequent filings with the Securities and Exchange
    [Show full text]
  • Pfizer and Mylan Will Own 57% and 43% of the New Company (“Newco”), Respectively
    DEAL PROFILE PFIZER | MYLAN VALUES 57% 43% $12.0bn PFIZER SHARE OF NEWCO MYLAN SHARE OF NEWCO NEW DEBT RAISED Pfizer Inc. (NYSE:PFE) Pfizer Inc. (“Pfizer”) is a pharmaceutical company that develops, manufactures, and sells products in internal medicine, vaccines, oncology, inflammation & immunology, and rare diseases. Upjohn, a subsidiary of Pfizer, is composed of Pfizer’s oral solid generics and off-patent drugs franchise, such as Viagra, Lipitor, and Xanax. Upjohn has a strong focus in emerging markets, and is headquartered in Shanghai, China. TEV: $265.4bn LTM EBITDA: $22.5bn LTM Revenue: $55.7bn Mylan N.V. (NASDAQ:MYL) Mylan N.V. (“Mylan”) is a pharmaceutical company that develops, manufactures, and commercializes generic, branded-generic, brand-name, and over-the-counter products. The company focuses in the following therapeutic areas: cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. Mylan was founded in 1961 and is headquartered in Canonsburg, PA. TEV: $23.9bn LTM EBITDA: $3.5bn LTM Revenue: $11.3bn Bourne Partners provides strategic and financial advisory services to BOURNE clients throughout the business evolution life cycle. In order to provide PARTNERS the highest level of service, we routinely analyze relevant industry MARKET trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, RESEARCH OTC, consumer health, and biotechnology sectors. On July 29, 2019, Pfizer announced the spin-off of its off-patent drug unit, Upjohn, in order to merge the unit with generic drug manufacturer, Mylan.
    [Show full text]
  • Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)- Based HIV Treatments in Developing Countries
    December 1, 2014 Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)- based HIV Treatments in Developing Countries PITTSBURGH and HYDERABAD, India, Dec. 1, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs. Tenofovir Alafenamide (TAF) is an investigational antiretroviral drug for the treatment of HIV-1 infection. The license being granted to Mylan extends to 112 countries, which together account for more than 30 million people living with HIV, representing 84% of those infected globally.1 Mylan CEO Heather Bresch said, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines and set new standards in health care. By working with partners like Gilead to help ensure access to innovative new products such as Tenofovir Alafenamide (TAF) in the countries hardest hit by this disease, we can help stem the tide of HIV/AIDS around the world." As part of the licensing agreement, on U.S. Food and Drug Administration (FDA) approval, Mylan will receive a technology transfer from Gilead, enabling the company to manufacture low-cost versions of Tenofovir Alafenamide (TAF), if approved as a single agent or in approved combinations containing Tenofovir Alafenamide (TAF) for developing markets. Phase III trials by Gilead Sciences met their primary objective supporting the potential for Tenofovir Alafenamide (TAF) to provide a new treatment option for individuals living with HIV.
    [Show full text]
  • 2020 Annual Report Products
    Products 2020 Annual Report From the CEO Dear Fellow Shareholders, Perrigo’s transformation to a pure-play Consumer Self-Care Company has come a long way LQMXVWWZRVKRUW\HDUV:HKDYHUHVWRUHGVXVWDLQDEOHWRSOLQHJURZWKGHOLYHUHGRQRXU¿QDQFLDO SURPLVHVUHFRQ¿JXUHGRXUSRUWIROLRRIEXVLQHVVHVXSGDWHGWKH,7LQIUDVWUXFWXUHDQGSURFHVVHV of the Company, expanded capacity, upgraded leadership talent, installed business intelligence capabilities, built a new product pipeline of over $500 million and re-instilled a sense of pride and energy among our 11,000 team members. Making this even more remarkable, is that we kept the WUDQVIRUPDWLRQRQWUDFNLQWKHIDFHRIWKHJOREDO&29,'SDQGHPLF,KRSH\RXDUHDVSURXGRI3HUULJR¶VJOREDOWHDP DV,DPIRUKRZWKH\ZRUNHGWRNHHSHDFKRWKHUVDIHNHSWRXUHVVHQWLDOSURGXFWVÀRZLQJDQGNHSWRXUWUDQVIRUPDWLRQ to a consumer self-care company on track through all of the personal and professional uncertainty that came their way LQ7KH\DUHKHURHV As a result of their efforts, Perrigo delivered strong net sales growth for the second year in a row in 2020 and World-wide Consumer sales reached a new record high. Equally important, the team stabilized adjusted operating income after a few years of decline even as we invested over $50 million in our business and overcame $35 million RIXQSODQQHGKHDGZLQGVGXHSULPDULO\WR&29,'UHODWHGVDIHW\FRVWVDQGEXVLQHVVLPSDFWIURPWKHZHDNFROG FRXJKDQGÀXVHDVRQUHODWHGWR&29,'¶VLPSDFWRQSXEOLFOLIH$OOLQDOOZHKDGDYHU\VWURQJ\HDU Our transformation efforts reached an essential milestone after the year closed when we announced the sale of RXU3UHVFULSWLRQ3KDUPDFHXWLFDOVEXVLQHVVWR$OWDULV&DSLWDO3DUWQHUV//&7KHWUDQVDFWLRQUHLQIRUFHVRXUDELOLW\
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • HEALTH BENEFITS Providing Value for Our Employees
    HEALTH BENEFITS Providing Value for Our Employees March 2017 Business Roundtable CEO members lead companies with more than $6 trillion in annual revenues and nearly 15 million employees. The combined market capitalization of Business Roundtable member companies is the equivalent of nearly one-quarter of total U.S. stock market capitalization, and Business Roundtable members invest $103 billion annually in research and development — equal to 30 percent of U.S. private R&D spending. Our companies pay $226 billion in dividends to shareholders and generate $412 billion in revenues for small and medium-sized businesses annually. Business Roundtable companies also make more than $7 billion a year in charitable contributions. Please visit us at www.brt.org, check us out on Facebook and LinkedIn, and follow us on Twitter. Copyright © 2017 by Business Roundtable HEALTH BENEFITS Providing Value for Our Employees March 2017 March 2017 DEAR BUSINESS LEADERS AND STAKEHOLDERS: I am pleased to share with you a new report highlighting what leading U.S. companies are doing to improve health outcomes for our employees and their families. America’s employer-sponsored health benefits system is the foundation of health care in the United States. Of the 209 million Americans who are covered by health insurance plans, 85 percent — or 177 million Americans* — receive health coverage through an employer. This report demonstrates many different ways employers are helping to drive a health care system that delivers better health care quality and value. I hope you find this report helpful. Sincerely, Brian Moynihan Chairman and Chief Executive Officer Bank of America * Bureau of Labor Statistics, Health Insurance Coverage in the United States: 2015, Current Population Reports, September 2016.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • Influential Women in Securities: Michele Johnson by Carmen Germaine
    Portfolio Media. Inc. | 111 West 19th Street, 5th Floor | New York, NY 10011 | www.law360.com Phone: +1 646 783 7100 | Fax: +1 646 783 7161 | [email protected] Influential Women In Securities: Michele Johnson By Carmen Germaine Law360, New York (June 17, 2016, 10:54 PM ET) -- Latham & Watkins LLP's Michele Johnson has fought shareholder challenges to billions of dollars' worth of acquisitions, but her most significant success to date came in representing Allergan as it fought a hostile takeover from Valeant and Pershing Square, developing an argument that blazed new ground in securities law and landing her among Law360's Influential Women in Securities Law. In the highly publicized case, Johnson and the Latham team were on the frontline defending Allergan Inc. from the hostile bid using a novel, untested theory — that Valeant Pharmaceuticals International Inc., billionaire activist investor Bill Ackman and Michele Johnson his fund Pershing Square Capital Management LP had committed insider trading in Latham & Watkins LLP developing their scheme. "It was all-out war," Johnson recalled. As Johnson explained, Valeant and Pershing publicly announced the takeover offer on April 22, 2014, a day after Pershing revealed that it had covertly amassed a 9.7 percent stake in Allergan. Allergan's board rebuffed the offer, concerned about the long-term viability of Valeant's strategy, which involved acquiring pharmaceutical rivals, slashing their research budgets and jacking up drug prices. As Valeant and Pershing pushed forward with their hostile bid, the Botox manufacturer filed a lawsuit to halt the purchase. The suit, filed Aug. 1, made immediate waves.
    [Show full text]
  • Signatory Companies
    PhRMA Direct to Consumer Advertising Principles Signatory Companies In October 2018, the PhRMA BoArd of Directors Adopted meAsures to enhAnce the PhRMA Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines. The revised, voluntAry Principles become effective on April 15, 2019. The revised, voluntAry Principles include A new guiding principle stAting thAt “[A]ll DTC television Advertising thAt identifies A prescription medicine by nAme should include direction as to where patients can find information about the cost of the medicine, such as a company- developed website, including the list price And Average, estimAted or typicAl pAtient out-of- pockets costs, or other context About the potentiAl cost of the medicine.” The Principles Also stAte thAt PhRMA will identify on its website All compAnies thAt voluntArily And independently commit to Abide by the Principles And will identify compAnies thAt complete, At the AppropriAte time, AnnuAl certificAtions thAt they hAve policies And procedures in plAce to foster compliAnce with the Principles. The following is A list of All signAtory compAnies who hAve Announced thAt they intend to Abide by the Principles: AbbVie GlAxoSmithKline Alexion Pharmaceuticals, Inc. Incyte CorporAtion Alkermes plc. Ipsen BiophArmAceuticAls, Inc. Allergan plc Johnson & Johnson Amgen Inc. Lundbeck Inc. Astellas Americas Merck & Co., Inc. AstrAZenecA PhArmAceuticAls LP NovArtis PhArmAceuticAls CorporAtion Bayer CorporAtion Novo Nordisk Inc. Biogen OtsukA AmericA PhArmAceuticAl, Inc. (OAPI) BioMArin PhArmAceuticAl Inc. Pfizer Inc Boehringer Ingelheim PharmAceuticAls, Inc. Purdue PhArmA L.P. Bristol-Myers Squibb CompAny Sanofi Celgene CorporAtion Sunovion Pharmaceuticals Inc. Daiichi SAnkyo, Inc. TakedA PhArmAceuticAls USA, Inc. EisAi Inc. TevA PhArmAceuticAls Eli Lilly And CompAny UCB EMD Serono .
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]